Clinical Trials Logo

Keratoacanthoma clinical trials

View clinical trials related to Keratoacanthoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05329792 Recruiting - Clinical trials for Merkel Cell Carcinoma

L19IL2/L19TNF in Skin Cancer Patients

IntriNSiC
Start date: March 9, 2023
Phase: Phase 2
Study type: Interventional

Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.

NCT ID: NCT03714828 Completed - Clinical trials for Squamous Cell Carcinoma

Study of TVEC in Patients With Cutaneous Squamous Cell Cancer

Start date: December 20, 2018
Phase: Phase 2
Study type: Interventional

This is single arm a Phase 2, single center study of talimogene laherparepvec (TVEC) to treat low risk cutaneous squamous cell carcinomas (cSCC).

NCT ID: NCT03630198 Completed - Plaque Psoriasis Clinical Trials

Pain Outcomes Following Intralesional Corticosteroid Injections

Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics. However, these injections can be quite painful, which leads many patients to discontinue treatment. Often, the injection involves a mixture of local anesthetic and corticosteroids despite a lack of evidence that the use of lidocaine improves pain. Due to the acidic pH, the lidocaine component of the injection can actually cause a significant burning sensation during the procedure. Lidocaine does not have anti-inflammatory properties and does not treat the underlying pathology. By including another medication, lidocaine also adds cost and risk to the procedure. The purpose of this study is to see if removing lidocaine from intralesional injections decreases the pain of injection.

NCT ID: NCT02978625 Active, not recruiting - Clinical trials for Merkel Cell Carcinoma

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Start date: September 27, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.